Evidence map›Paper›PMID 27815268›Full record

ArticleJournal of the American Heart Association2016

Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.

Jan H Cornel, E Magnus Ohman, Benjamin Neely, Joseph A Jakubowski, Deepak L Bhatt, Harvey D White, Diego Ardissino, Keith A A Fox, Dorairaj Prabhakaran, Paul W Armstrong and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00699998 (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00699998 phase3completednot on this map

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed

TypeinterventionalSponsorEli Lilly and CompanyRan2008 to 2012Enrolled9,326ConditionsAcute Coronary SyndromeArmsClopidogrel, Prasugrel, Commercially-available Aspirin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 8 countries.

Jan H CornelMedisch Centrum Alkmaar, Alkmaar, The Netherlands.
E Magnus OhmanDuke Clinical Research Institute, Durham, NC.
Benjamin NeelyDuke Clinical Research Institute, Durham, NC.
Joseph A JakubowskiEli Lilly and Company, Indianapolis, IN.
Deepak L BhattBrigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA.
Harvey D WhiteGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
Diego ArdissinoDivision of Cardiology, Azienda Ospedaliero-Universitaria di Parma, Italy.
Keith A A FoxCentre for Cardiovascular Science, University of Edinburgh, Scotland, UK.
Dorairaj PrabhakaranCentre for Chronic Disease Control and Public Health Foundation of India, New Delhi, India.
Paul W ArmstrongCanadian VIGOUR Centre and Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.
David ErlingeDepartment of Cardiology, Lund University, Lund, Sweden.
Udaya S TantrySinai Center for Thrombosis Research, Baltimore, MD.
Paul A GurbelSinai Center for Thrombosis Research, Baltimore, MD.
Matthew T RoeDuke Clinical Research Institute, Durham, NC matthew.roe@duke.edu.
Duke Medical Center · USSinai Hospital · USAuckland City Hospital · NZCentre for Chronic Disease Control · INClinical Research Institute · USEli Lilly (United States) · USHarvard University · USLund University · SEMedisch Centrum Alkmaar · NLOspedale di Parma · ITUniversity of Alberta · CAUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between "on-treatment" low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary syndromes remains uncertain, especially for patients who do not undergo percutaneous coronary intervention. METHODS AND

resultsWe analyzed 2428 medically managed acute coronary syndromes patients from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial who had serial platelet reactivity measurements (P2Y

conclusionsAmong medically managed non-ST-segment elevation acute coronary syndromes patients receiving prolonged dual antiplatelet therapy, PRU values were not significantly associated with the long-term risk of major bleeding events, suggesting that low on-treatment platelet reactivity does not independently predict serious bleeding risk. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00699998.

Indexed as

Acute Coronary SyndromeAgedAngina, UnstableAspirinBlood PlateletsClopidogrelDrug Therapy, CombinationFemaleHemorrhageHumansLongitudinal StudiesMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Function TestsAspirinClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochlorideTiclopidineDAPThemorrhageplatelet

Identifiers

PMID27815268
PMCPMC5210327
OpenAlexW2547486604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.